Last reviewed · How we verify
Mixed Gonococcal and Chlamydia Infection of the Cervix — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Ofloxacine | Ofloxacine | Assistance Publique - Hôpitaux de Paris | Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 2 drugs in Mixed Gonococcal and Chlamydia Infection of the Cervix
- Assistance Publique - Hôpitaux de Paris · 1 drug in Mixed Gonococcal and Chlamydia Infection of the Cervix
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Mixed Gonococcal and Chlamydia Infection of the Cervix:
- Mixed Gonococcal and Chlamydia Infection of the Cervix treatment updates — RSS
- Mixed Gonococcal and Chlamydia Infection of the Cervix treatment updates — Atom
- Mixed Gonococcal and Chlamydia Infection of the Cervix treatment updates — JSON
Cite this brief
Drug Landscape (2026). Mixed Gonococcal and Chlamydia Infection of the Cervix — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/mixed-gonococcal-and-chlamydia-infection-of-the-cervix. Accessed 2026-06-11.
Related
- Mixed Gonococcal and Chlamydia Infection of the Cervix full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing